Amazon Stock Price Today – Why Homology Medicines Stock Is Sinking Today
Shares of Homology Medicines (NASDAQ: FIXX) were sinking 17.8% lower as of 12:01 p.m. EDT on Wednesday. The decline came after the company announced the pricing of its latest public stock offering.
Biotech stocks usually fall after public stock offerings are announced. The issuance of new shares dilutes the value of existing shares. Just how much they fall depends on how much dilution is on the way.
Image source: Getty Images.
Neither Homology Medicines’ press release nor its prospectus filed with the U.S. Securities and Exchange Commission (SEC) provided many details about the pricing of the stock offering. However, the company did explain that it plans to use net proceeds from the offering to advance the clinical testing of its pipeline candidates, expand its intellectual property portfolio, and potentially boost its manufacturing capacity.
The company is currently evaluating gene therapy candidate HMI-102 in a phase 2 study for treating genetic metabolism disorder phenylketonuria (PKU) in adults. It also has other experimental gene therapies in preclinical development.
Homology plans to advance two of its preclinical candidates into phase 1/2 studies this year. HMI-203 is an experimental gene-editing therapy that, like lead candidate HMI-102, targets PKU. HMI-203 is another investigational gene therapy that targets rare genetic disorder Hunter syndrome.
10 stocks we like better than Homology Medicines
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Homology Medicines wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of February 24, 2021
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.